Immune response after influenza vaccination in children with cancer

Akinobu Matsuzaki, Aiko Suminoe, Yuhki Koga, Naoko Kinukawa, Koichi Kusuhara, Toshiro Hara

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Purpose. To assess the immune response to inactivated trivalent split influenza vaccine in children with cancer. Procedures. Forty-four children with various types of malignancies received two doses of influenza vaccine 2-4 weeks apart. Hemagglutinin-inhibition (HI) antibody titers were determined in paired sera obtained just before the first vaccination and 4 weeks after the second vaccination. Results. Influenza vaccine was administered to all children without any serious adverse effects. Protective titer rates (proportion of patients achieving antibody titers ≥40 among those with pre-vaccination titers <40) and response rates (proportion of patients with fourfold or more antibody rise) were 72% and 65% for H1N1, 60% and 40% for H3N2, and 38% and 46% for influenza B, respectively. However, patients on chemotherapy showed a significantly lower immune response to influenza A than those having completed chemotherapy; protection titer rates were 42% versus 90% for H1N1 (P = 0.006) and 25% versus 83% for H3N2 (P = 0.019). For influenza B, patients with low IgG showed a lower response rate than those with high IgG (29% vs. 61%, P = 0.040). Multivariate analysis revealed that factors significantly associated with a lower immune response were low IgG (P < 0.001) and administration of chemotherapy (P = 0.003) for H1N1, administration of chemotherapy (P = 0.008) for H3N2, and low white blood cell (WBC) count (P = 0.030) and low IgG (P = 0.030) for influenza B. Conclusions. Influenza vaccination given to children with cancer was safe and induced immune reaction comparable to healthy children, although patients on chemotherapy and/or with chemotherapy-related conditions had a limited ability to produce a sufficient immune response.

Original languageEnglish
Pages (from-to)831-837
Number of pages7
JournalPediatric Blood and Cancer
Volume45
Issue number6
DOIs
Publication statusPublished - Oct 1 2005

Fingerprint

Human Influenza
Vaccination
Drug Therapy
Influenza Vaccines
Immunoglobulin G
Neoplasms
Antibodies
Hemagglutinins
Leukocyte Count
Multivariate Analysis
Serum

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Matsuzaki, A., Suminoe, A., Koga, Y., Kinukawa, N., Kusuhara, K., & Hara, T. (2005). Immune response after influenza vaccination in children with cancer. Pediatric Blood and Cancer, 45(6), 831-837. https://doi.org/10.1002/pbc.20470

Immune response after influenza vaccination in children with cancer. / Matsuzaki, Akinobu; Suminoe, Aiko; Koga, Yuhki; Kinukawa, Naoko; Kusuhara, Koichi; Hara, Toshiro.

In: Pediatric Blood and Cancer, Vol. 45, No. 6, 01.10.2005, p. 831-837.

Research output: Contribution to journalArticle

Matsuzaki, A, Suminoe, A, Koga, Y, Kinukawa, N, Kusuhara, K & Hara, T 2005, 'Immune response after influenza vaccination in children with cancer', Pediatric Blood and Cancer, vol. 45, no. 6, pp. 831-837. https://doi.org/10.1002/pbc.20470
Matsuzaki, Akinobu ; Suminoe, Aiko ; Koga, Yuhki ; Kinukawa, Naoko ; Kusuhara, Koichi ; Hara, Toshiro. / Immune response after influenza vaccination in children with cancer. In: Pediatric Blood and Cancer. 2005 ; Vol. 45, No. 6. pp. 831-837.
@article{27e720a30cbf4a1e8d651baa4fefc48b,
title = "Immune response after influenza vaccination in children with cancer",
abstract = "Purpose. To assess the immune response to inactivated trivalent split influenza vaccine in children with cancer. Procedures. Forty-four children with various types of malignancies received two doses of influenza vaccine 2-4 weeks apart. Hemagglutinin-inhibition (HI) antibody titers were determined in paired sera obtained just before the first vaccination and 4 weeks after the second vaccination. Results. Influenza vaccine was administered to all children without any serious adverse effects. Protective titer rates (proportion of patients achieving antibody titers ≥40 among those with pre-vaccination titers <40) and response rates (proportion of patients with fourfold or more antibody rise) were 72{\%} and 65{\%} for H1N1, 60{\%} and 40{\%} for H3N2, and 38{\%} and 46{\%} for influenza B, respectively. However, patients on chemotherapy showed a significantly lower immune response to influenza A than those having completed chemotherapy; protection titer rates were 42{\%} versus 90{\%} for H1N1 (P = 0.006) and 25{\%} versus 83{\%} for H3N2 (P = 0.019). For influenza B, patients with low IgG showed a lower response rate than those with high IgG (29{\%} vs. 61{\%}, P = 0.040). Multivariate analysis revealed that factors significantly associated with a lower immune response were low IgG (P < 0.001) and administration of chemotherapy (P = 0.003) for H1N1, administration of chemotherapy (P = 0.008) for H3N2, and low white blood cell (WBC) count (P = 0.030) and low IgG (P = 0.030) for influenza B. Conclusions. Influenza vaccination given to children with cancer was safe and induced immune reaction comparable to healthy children, although patients on chemotherapy and/or with chemotherapy-related conditions had a limited ability to produce a sufficient immune response.",
author = "Akinobu Matsuzaki and Aiko Suminoe and Yuhki Koga and Naoko Kinukawa and Koichi Kusuhara and Toshiro Hara",
year = "2005",
month = "10",
day = "1",
doi = "10.1002/pbc.20470",
language = "English",
volume = "45",
pages = "831--837",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Immune response after influenza vaccination in children with cancer

AU - Matsuzaki, Akinobu

AU - Suminoe, Aiko

AU - Koga, Yuhki

AU - Kinukawa, Naoko

AU - Kusuhara, Koichi

AU - Hara, Toshiro

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Purpose. To assess the immune response to inactivated trivalent split influenza vaccine in children with cancer. Procedures. Forty-four children with various types of malignancies received two doses of influenza vaccine 2-4 weeks apart. Hemagglutinin-inhibition (HI) antibody titers were determined in paired sera obtained just before the first vaccination and 4 weeks after the second vaccination. Results. Influenza vaccine was administered to all children without any serious adverse effects. Protective titer rates (proportion of patients achieving antibody titers ≥40 among those with pre-vaccination titers <40) and response rates (proportion of patients with fourfold or more antibody rise) were 72% and 65% for H1N1, 60% and 40% for H3N2, and 38% and 46% for influenza B, respectively. However, patients on chemotherapy showed a significantly lower immune response to influenza A than those having completed chemotherapy; protection titer rates were 42% versus 90% for H1N1 (P = 0.006) and 25% versus 83% for H3N2 (P = 0.019). For influenza B, patients with low IgG showed a lower response rate than those with high IgG (29% vs. 61%, P = 0.040). Multivariate analysis revealed that factors significantly associated with a lower immune response were low IgG (P < 0.001) and administration of chemotherapy (P = 0.003) for H1N1, administration of chemotherapy (P = 0.008) for H3N2, and low white blood cell (WBC) count (P = 0.030) and low IgG (P = 0.030) for influenza B. Conclusions. Influenza vaccination given to children with cancer was safe and induced immune reaction comparable to healthy children, although patients on chemotherapy and/or with chemotherapy-related conditions had a limited ability to produce a sufficient immune response.

AB - Purpose. To assess the immune response to inactivated trivalent split influenza vaccine in children with cancer. Procedures. Forty-four children with various types of malignancies received two doses of influenza vaccine 2-4 weeks apart. Hemagglutinin-inhibition (HI) antibody titers were determined in paired sera obtained just before the first vaccination and 4 weeks after the second vaccination. Results. Influenza vaccine was administered to all children without any serious adverse effects. Protective titer rates (proportion of patients achieving antibody titers ≥40 among those with pre-vaccination titers <40) and response rates (proportion of patients with fourfold or more antibody rise) were 72% and 65% for H1N1, 60% and 40% for H3N2, and 38% and 46% for influenza B, respectively. However, patients on chemotherapy showed a significantly lower immune response to influenza A than those having completed chemotherapy; protection titer rates were 42% versus 90% for H1N1 (P = 0.006) and 25% versus 83% for H3N2 (P = 0.019). For influenza B, patients with low IgG showed a lower response rate than those with high IgG (29% vs. 61%, P = 0.040). Multivariate analysis revealed that factors significantly associated with a lower immune response were low IgG (P < 0.001) and administration of chemotherapy (P = 0.003) for H1N1, administration of chemotherapy (P = 0.008) for H3N2, and low white blood cell (WBC) count (P = 0.030) and low IgG (P = 0.030) for influenza B. Conclusions. Influenza vaccination given to children with cancer was safe and induced immune reaction comparable to healthy children, although patients on chemotherapy and/or with chemotherapy-related conditions had a limited ability to produce a sufficient immune response.

UR - http://www.scopus.com/inward/record.url?scp=26244442458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26244442458&partnerID=8YFLogxK

U2 - 10.1002/pbc.20470

DO - 10.1002/pbc.20470

M3 - Article

VL - 45

SP - 831

EP - 837

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -